This September 2026 FAQ explains what Parkinson's disease is, how clinicians diagnose it, and which treatments have documented roles. Parkinson's is a progressive nervous-system disorder caused by damage and death in dopamine-producing brain cells that help control purposeful movement. Treatment can improve symptoms, but no available therapy has been shown to stop or slow disease progression. Newer options and clinical trials serve specific purposes; they should not be mistaken for cures.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What symptoms can Parkinson's cause?
- Who develops Parkinson's, and what causes it?
- How is Parkinson's diagnosed?
- What can medication—and newer treatments—actually do?
- Who might consider deep-brain stimulation or a clinical trial?
What symptoms can Parkinson's cause?
Common movement symptoms include tremor, muscle rigidity, slowed movement, and balance problems. Symptoms and their response to treatment can differ among individuals. Parkinson's also has nonmovement symptoms.
Constipation, reduced smell, acting out dreams during REM sleep, depression, fatigue, and cognitive changes may occur. Some can appear before movement problems, according to the National Institute of Neurological Disorders and Stroke. A useful symptom record should note:.
- What changed and when it began
- Whether symptoms affect one side or both
- Falls, balance problems, sleep changes, or constipation
- Changes in mood, memory, smell, or daily functioning
- Medication timing and whether symptoms improve afterward
Who develops Parkinson's, and what causes it?
Risk increases with age, and average onset occurs in the early-to-mid 60s. Men are affected more often than women. A small proportion of people develop early-onset Parkinson's before age 50. The exact cause remains unknown.
Some cases are inherited, but most late-onset cases have no clear genetic cause. The National Institute of Environmental Health Sciences describes Parkinson's as likely involving an interaction between genetic and environmental factors. A diagnosis does not, by itself, identify why one person developed the disease. Family history may inform a clinical discussion, but it does not explain every case.
How is Parkinson's diagnosed?
There is no single test that definitively confirms Parkinson's. Clinicians rely mainly on medical history and a neurological examination, including the pattern of movement and nonmovement symptoms. Skin or spinal-fluid tests that detect alpha-synuclein can provide supporting evidence.
📨 Get Free Parkinson's Guides Alerts
Free · No spam · Unsubscribe anytime
DaT imaging can also help evaluate the brain's dopamine system. However, these tools cannot reliably separate Parkinson's from every disorder that produces similar symptoms. Before an appointment, bring a complete medication list and a timeline of changes. If symptoms vary during the day, note when they are best or worst and record a short video when safe and practical.
What can medication—and newer treatments—actually do?
Carbidopa-levodopa remains the main drug treatment and often improves early movement symptoms. It increases dopamine activity but does not replace lost neurons, stop progression, or relieve every tremor. The FDA's 2025 review states that no treatment has been shown to slow or halt Parkinson's progression.
Available therapies should therefore be understood as symptom management rather than a cure. Vyalev, a continuous foscarbidopa/foslevodopa treatment, received FDA approval on October 16, 2024, for motor fluctuations in adults with advanced Parkinson's. It is an option for that defined group—not a general early-disease treatment or a cure.
Who might consider deep-brain stimulation or a clinical trial?
Deep-brain stimulation, or DBS, uses an implanted system to influence targeted brain activity. FDA authorization for adaptive DBS applies as an add-on therapy when Parkinson's has lasted at least four years, responds to levodopa, and medication does not adequately control motor complications. DBS may reduce some symptoms, but it does not cure Parkinson's.
A reader considering it should ask whether symptoms respond to levodopa, which complications remain uncontrolled, and whether the expected benefit justifies an implanted treatment. Prasinezumab, an experimental therapy for early Parkinson's, was in a recruiting randomized Phase III trial as of May 6, 2026. The ClinicalTrials.gov record documents active investigation—not proven benefit or regulatory approval. Anyone considering a trial should confirm its purpose, eligibility rules, treatment burden, and possibility of receiving a placebo.
You Might Also Like
- Diet and Nutrition for Parkinson’s Disease FAQ for August 2026: Source-Checked Answers to Common Questions
- Parkinson’s Disease Treatment FAQ: Common Questions and Evidence-Based Answers
- What Is New With Parkinson’s Disease in September 2026? Latest NIH, FDA, and trial records and Key Takeaways